Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02433171
Other study ID # 1401013294
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date January 2015
Est. completion date June 27, 2017

Study information

Verified date May 2019
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing lesions. These state-of-the-art imaging tools will be used in combination with standard magnetic resonance imaging (MRI), MR spectroscopy (MRS) and FDG-PET (fluorodeoxyglucose).


Description:

The investigators hypothesize that by using two different PET tracers, one sensitive to tumor metabolic activity, and one sensitive to inflammatory processes, investigators can separately identify metabolically active tumor from radiation necrosis related inflammation. This can be accomplished with quantitative assessments of tracer uptake using kinetic modeling techniques, as well as by high-resolution imaging to assess the distribution of tracer uptake in the tumor region. All participants in the study will have the receive the same diagnostic tests.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date June 27, 2017
Est. primary completion date June 27, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients over 18 years with brain metastases from melanoma or non-small cell lung cancer

- Patients must have had SRS and regrowth in at least one lesion > 0.5 cm in greatest dimension and fall into one of two categories: a) patient is deemed clinically appropriate for surgical intervention (biopsy or craniotomy) OR b) patient is asymptomatic and has a life expectancy of > 6 months so that serial follow-up imaging is appropriate

- Willingness to participate in imaging studies

- Able to give informed consent

Exclusion Criteria:

- Subjects with history of prior radiation exposure for research purposes within the past year, such that participation in this study would place them over the FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year.

- Subjects who are pregnant or currently breastfeeding

- Women of child-bearing age who are sexually active, unless they agree to two forms of contraception, and have a negative urine pregnancy test at screening and on the days of the PET imaging

- Patients unable to undergo MRI with gadolinium-based contrast for standard clinical reasons which include:

- Cardiac pacemaker, aneurysm clip, cochlear implants, Intra Uterine Device (IUD), shrapnel, neurostimulators, defibrillator, artificial heart valve, or history of metal fragments in eyes.

- Pregnancy

- Body size too large for closed MRI

- Known hepatic fibrosis.

- Claustrophobia

- Contraindication to MR contrast agents: eGFR (epidermal growth factor receptor) < 30 by the Cockcroft- Gault formula if > 60 years old or with chronic renal disease

- Anaphylactic allergy to gadolinium

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Standard of Care FDG-PET Imaging
[11C]Methionine [11]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. [11C]PBR28 [12]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.

Locations

Country Name City State
United States Yale University New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Regrowing Tumor Rate from Radiation Effect 6 months
See also
  Status Clinical Trial Phase
Withdrawn NCT01913067 - Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC Phase 2
Completed NCT02662725 - Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases Phase 2
Completed NCT00406835 - Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases Phase 3
Completed NCT01724801 - Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer Phase 3
Completed NCT00219297 - Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02328300 - FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
Terminated NCT01324635 - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Phase 1
Terminated NCT01894633 - Study of Whole-brain Irradiation With Chloroquine for Brain Metastases Phase 2
Recruiting NCT02681549 - Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Phase 2
Terminated NCT02279992 - Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases Early Phase 1
Completed NCT02913534 - Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy N/A
Completed NCT01942980 - Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer Phase 3
Terminated NCT01363557 - Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis N/A
Active, not recruiting NCT05102747 - Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. N/A
Recruiting NCT01891708 - VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer N/A
Completed NCT01508221 - Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis Phase 2
Completed NCT00587964 - Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Phase 2
Not yet recruiting NCT06462079 - Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases Phase 2
Not yet recruiting NCT02832635 - A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases Phase 2
Completed NCT01395407 - Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases Phase 1